

DAFTAR PUSTAKA

- Abbott, J.D. 2015. Measuring the Effectiveness of Percutaneous Coronary Intervention. *Circ. Cardiovasc. Interv.*8: e003024.
- Abdelaal, E., Rao, S.V., Gilchrist, I.C., Bernat, I., Shroff, A., *et al.*, 2013. Same-day discharge compared with overnight hospitalization after uncomplicated percutaneous coronary intervention: A systematic review and metaanalysis. *JACC. Cardiovasc. Interv.* 6: 99–112.
- Abdelnoor, M., Andersen, J.G., Arnesen, H., Johansen, O. 2017. Early discharge compared with ordinary discharge after percutaneous coronary intervention – a systematic review and meta-analysis of safety and cost. *Vasc. Health. Risk. Manag.* 13: 101–9.
- Alhuseiny, AH., Al-Nimer, MSM., Al-Neamy, SIA. 2015. Assessment of Serum Cystatin C Levels in Newly Diagnosed Acute Myocardial Infarction at the Onset and at the Time of Hospital Discharge. *Cardiol Res.* 6(1):226-231.
- Amin, A.P., McNeely, C., Spertus, J.A., Bach, R.G., Frogge, N., *et al.*, 2020. Incremental Cost of Acute Kidney Injury after Percutaneous Coronary Intervention in the United States. *Am. J. Cardiol.* 125(1): 29-33.
- Bangalore, S., Qin, J., Sloan, S., Murphy, SA., Cannon, CP. 2010. What is the optimal blood pressure in patients after acute coronary syndromes?: relationship of blood pressure and cardiovascular events in the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction (PROVE IT-TIMI) 22 trial. *Circulation.* 122(21):pp. 2142–2151.
- Bavishi, C., Panwar, S., Messerli, F.H., Bangalore, S. 2015. Meta-analysis of comparison of the newer oral P2Y12 inhibitors (Prasugrel or Ticagrelor) to clopidogrel in patients with non-ST-elevation acute coronary syndrome. *Am. J. Cardiol.* 116: 809–17.
- Bhatt, DI. 2018. Percutaneous Coronary Intervention in 2018. *JAMA.* 319(20): 2127-8.
- Biswas, S., Andrianoloulos, N., Dinh, D., Duffy, SJ., Lefkovits, J *et al.* 2019. Association of Body Mass Index and Extreme Obesity With Long-Term Outcomes Following Percutaneous Coronary Intervention. *J Am Heart Assoc.* 8:e012860.
- Brennan, J.M., Curtis, J.P., Dai, D., Fitzgerald, S., Khandelwal, A.K., *et al.*, 2013. Enhanced mortality risk prediction with a focus on high-risk percutaneous coronary intervention: Results from 1,208,137 procedures in the NCDR (National Cardiovascular Data Registry). *J. Am. Coll. Cardiol. Interv.* 6: 790–9.
- Briguori, C., Visconti, G., Rivera, N., Focaccio, A., Golia, B., *et al.*, 2010. Cystatin C and Contrast-Induced Acute Kidney Injury. *Circulation.* 121: 2117-22.
- Bundhun, PK., Gupta, C. Xu, GM. 2017. Major Adverse Cardiac Events and Mortality in Chronic Obstructive Pulmonary Disease Following Percutaneous Coronary Intervention: A Systematic Review and Meta Analysis. *BMC Cardiovascular Disord.* 17(1):191.
- Cepeda, J., Iparraguirre, ST., Iranzo, RM., Rodriguez, EF., Garcia, AR *et al.* 2010. Cystatin C and Cardiovascular Risk in the General Population. *Esp Cardiol.* 63(4):415-22.
- Correa, S., Morrow, D.A., Braunwald, E., Davies, R.Y., Goodrich, E.L., *et al.*, 2018. Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome. *J. Am. Heart. Assoc.* 7: e009077.
- DeGeare, VS., Judith, A., Boura, MS., Lorelei, L., William, W., Cindy, L., *et al.*, 2001. Predictive Value of the Killip Classification in Patients Undergoing Primary

- Percutaneous Coronary Intervention for Acute Myocardial Infarction. *American Journal of Cardiology*. 87(9):1035-8.
- Diputra, MAR., Wita, W., Aryadana, W. 2018. Karakteristik Penderita Sindroma Koroner Akut di RSUP Sanglah Denpasar tahun 2016. *E-Jurnal Medika*.7 (10):1-10.
- Ferrante, G., Rao, S.V., Jüni, P., Da Costa, B.R., Reimers, B., *et al.*, 2016. M. Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: A meta-analysis of randomized trials. *JACC. Cardiovasc. Interv.* 9: 1419–34.
- Franco, J.J., Abisse, S.S., Ruisi, P., Abbott. J.D. 2014. Infectious complications of percutaneous cardiac procedures. *Int. Cardiol.* 6(5): 445-52.
- Fresco, C F., Avanzini, S. Bosi *et al.* 1996. Prognostic value of a history of hypertension in 11,483 patients with acute myocardial infarction treated with thrombolysis. *GISSI-2 Investigators. International Journal of Hypertension*. 14(6): 743– 750.
- Fuchs, S., Stabile, E., Kinnaird, T.D., Mintz, G.S., Gruberg, L., 2002. Stroke Complicating Percutaneous Coronary Interventions Incidence, Predictors, and Prognostic Implications. *Circulation*.106: 86-91
- Ghirabeh, K.A., Hamadah, A.M., El-Zoghby, Z.M., Lieske, J.C., Larson, T.M., *et al.*, 2018. Cystatin C Predicts Renal Recovery Earlier Than Creatinine Among Patients With Acute Kidney Injury. *Kidney. Int. Rep.* 3: 337–42.
- Giannini, F., Candilio, L., Mitomo, S., Ruparella, N., Chieffo, A., Baldetti, L., *et al.*, 2018. A Practical Approach to the Management of Complications During Percutaneous Coronary Intervention. *J. Am. Coll. Cardiol. Interv.* 11(18); 1797-810.
- Godino, C., Colombo, A., 2015. Complications of Percutaneous Coronary Intervention. In: Lanzer, P. (Eds.): *PanVascular Medicine*, pp: 2297-322. Springer, Berlin.
- Grossman, P.M., Ali, S.S., Aronow, H.D., Boros, M., Nypaver, T.J., *et al.*, 2017. Contrast-induced nephropathy in patients undergoing endovascular peripheral vascular intervention: incidence, risk factors, and outcomes as observed in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. *J. Interv. Cardiol.* 30: 274–80.
- Hulley, S.B., Cummings, S.R., Browner, W.S., Grady, D., Newman, T.B. 2013. Designing clinical research : an epidemiologic approach. 4th ed. Philadelphia: *Lippincott Williams & Wilkins*. 80-85
- Isik, T. dan Demirtas, A.O. 2016. What is the optimal length of stay in hospital after primary PCI. *Int. J. Cardiol.* 221: 75–6.
- Jabara, R., Gadesam, R., Pendyala, L., Chronos, N., Crisco, L.V., *et al.*, 2008. Ambulatory discharge after transradial coronary intervention: Preliminary US single-center experience (Same-day TransRadial Intervention and Discharge Evaluation, the STRIDE Study). *Am. Heart. J.* 156:1141–6.
- Jabara, R., Gadesam, R., Pendyala, L., Chronos, N., Crisco, LV *et al.* 2008. Ambulatory discharge after transradial coronary intervention: Preliminary US single-center experience (Same-day TransRadial Intervention and Discharge Evaluation, the STRIDE Study). *J Am Heart Assoc.* 156(6):1141-6.
- Jacobson, K.M., Long, K.L., McMurty, E.K., Naessens, J.M., Rihal, C.S. 2007. The economic burden of complications during percutaneous coronary intervention. *Qual. Saf. Health. Care.* 16(2): 154–9.
- Jensen, MK., Chiove, SE., Rimm, EB., Dethlefsen, C., Tjonneland, A *et al.* 2008. Obesity, Behavioral Lifestyle Factors, and Risk of Acute Coronary Events. *Circulation AHA Journal.* 117:3062-3069.

- Karabulut, A., Cakmak, M., Uzunlar, B., Bilici, A. 2011. What is the optimal length of stay in hospital for ST elevation myocardial infarction treated with primary percutaneous coronary intervention? *Cardiol. J.* 18: 378–84.
- Keaney, JJ., Hannon, CM., Murray, PT. 2013. Contrast-induced acute kidney injury: how much contrast is safe?. *Oxford University Press on.* 1376-83.
- Kidney Disease Improving Global Outcomes (KDIGO), 2012. KDIGO Clinical practice guideline for acute kidney injury. *Kidney. Int. Suppl.* 2:131–8.
- Knight, E.L., Verhave, J.C., Spiegelman, D., Hillege, H.L., de Zeeuw, D., *et al.*, 2004. Factors influencing cystatin c serum levels other than renal function and the impact on renal function measurement. *Kidney. Intl.* 65: 1416–21.
- Lincoff, A.M., Bittl, J.A., Harrington, R.A., Feit, F., Kleiman, N.S., Jackman, J.D., *et al.*, 2003. Bivalirudin and provisional glycoprotein iib/iiiia blockade compared with heparin and planned glycoprotein iib/iiiia blockade during percutaneous coronary intervention. *J. Am. Med. Assoc.* 289:853–63
- Liu, Y., Chen, K.H., Chen, S.Q., Chen, L.L., Duan, C.Y., *et al.*, 2017. Predictive value of post-procedural early (within 24 h) increase in cystatin C for contrast-induced acute kidney injury and mortality following coronary angiography or intervention. *Oncotarget.* 8(65): 109762-71.
- Magill, SS., Edwards, JR., Bamberg, W., Beldavs, ZG., Dumyati, G *et al.* 2014. Multistate point-prevalence survey of health care–associated infections. *N. Engl. J. Med.* 370: 1198–1208.
- Marenzi, G., Ferrari, C., Marana, I., Assanelli, E., De Metrio, M., Teruzzi, G., *et al.*, 2012. Prevention of contrast nephropathy by furosemide with matched hydration: the mythos (induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention) trial. *JACC. Cardiovasc. Interv.* 5:90–7
- Martucheli, K.F.C., Domingueti, C.P. 2018. Clinical Usefulness of Cystatin C to Assess the Prognosis of Acute Coronary Syndromes: A Systematic Review and Meta-Analysis. *Int. J. Cardiovas. Sci.* 31(3): 290-307.
- Matsushita, K., van der Velde, M., Astor, B.C., Woodward, M., Levey, A.S., *et al.* 2010. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet.* 375(9731): 2073-81.
- Mehran, R., Aymong, E.D., Nikolsky, E., Lasic, Z., Iakovou, I., Fahy, M., *et al.*, 2004. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J. Am. Coll. Cardiol.* 44:1393–9.
- Muñoz, P., Blanco, J.R., Rodríguez-Creixéms, M., Garcia, E., Delcan, J.L., Bouza, E. 2001. Bloodstream infections after invasive nonsurgical cardiologic procedures. *Arch. Intern. Med.* 161(17), 2110–5
- Mussap, M., Plebani, M. 2004. Biochemistry and clinical role of human cystatin C. *Crit. Rev. Clin. Lab. Sci.* 41: 467-550.
- Navarese, E.P., Schulze, V., Andreotti, F., Kowalewski, M., Kołodziejczak, M., *et al.*, 2015. Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome. *JACC. Cardiovasc. Interv.* 8: 201–13.
- Navarro, MFJ., Jimenez, FL., Belmante, LMP., Lennon, RJ., Melean, CD *et al.* 2017. Benefits of Cardiac Rehabilitation on Cardiovascular Outcomes in Patients With Diabetes Mellitus After Percutaneous Coronary Intervention. *J Am Heart Assoc.* 6:e006404.

- Neumann, F.J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A.P., *et al.*, 2019. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eu. Heart. J.* 40: 87–165
- Newman, D.J. 2002. Cystatin C. *Ann. Clin. Biochem.* 39: 89-104.
- Odden, MC., Tager, IB., Gansevoort, RT., Bakker, S.J.L., Katz, R *et al.* 2010. Age and cystatin C in healthy adults: a collaborative study. *Nephrol Dial Transplant.* 25: 463–469.
- OECD/European Union, 2016. Health at a Glance: Europe 2016: State of Health in the EU Cycle [internet]. Paris: *OECD Publishing*; [cited 24 Januari 2020]. Available from: <https://doi.org/10.1787/9789264265592-en>.
- Piccolo, R., Bona, K.R., Efthimiou, O., Varenne, O., Baldo, A., *et al.*, 2019. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. *Lancet.* 393: 2503–10.
- Pistolesi, V., Regolisti, G., Morabito, S., Gandolfini, I., Corrado, S., Piotti, G., *et al.*, 2018. Contrast medium induced acute kidney injury: a narrative review. *Journal of nephrology:* 1-16
- Popma, J.J., Kuntz, R.E., Baim, D.S. 2002. A Decade of Improvement in the Clinical Outcomes of Percutaneous Coronary Intervention for Multivessel Coronary Artery Disease. *Circulation.* 106(13): 1592-4.
- Popma, J.J., Satler, L.F., Pichard, A., Kent, K.M., Campbell, A., Chuang, Y.C., *et al.*, 1993. Vascular complications after balloon and new device angioplasty. *Circulation.* 88:1569–78.
- Prabhakar, S.K. dan Abbott, D. 2012. Factors influencing the outcomes of percutaneous coronary intervention in the stent era. *Interv. Cardiol.* 4(5):557–68.
- Přeček, J., Hutyra, M., Sněhota, M., Jarkovský, J., Adam, T., *et al.*, 2018. Prognostic value of cystatin C in relation to other markers of renal function in early prediction of hospital mortality and major cardiac adverse events in patients with ST elevation myocardial infarction treated by primary percutaneous coronary intervention. *Cor. Et. Vasa.* 60(4): e352-60.
- Putot, A., Chague, F., Manckoundia, P., Cottin, Y., Zeller, M. 2019. Post-Infectious Myocardial Infarction: New Insights for Improved Screening. *Journal of Clinical Medicine.* 8:827.
- Ralapanawa, U., Kumarasiri, P.V.R., Jayawickreme, K.P., Kumarihamy, P., Wijeratne, Y *et al.* 2019. Epidemiology and risk factors of patients with types of acute coronary syndrome presenting to a tertiary care hospital in Sri Lanka. *BMC Cardiovascular Disorders.* 19:229.
- Rao, S.V., McCoy, L.A., Spertus, J.A., Krone, R.J., Singh, M., *et al.*, 2013. An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: A report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry. *JACC. Cardiovasc. Interv.* 6: 897–904.
- Ratib, K., Mamas, M.A., Routledge, H.C., Ludman, P.F., Fraser, D., Nolan, J. 2012. Influence of access site choice on incidence of neurologic complications after percutaneous coronary intervention. *Am. Heart. J.* 165:317–24.
- Ravn, B., Prowle, JR., Martensson, J., Martling, CR., Bell, M. 2017. Superiority of Serum Cystatin C Over Creatinine in Prediction of Long-Term Prognosis at Discharge From ICU. *Critical Care Medicine Journal.* 20(3):1-9.
- Redon., Oliva, MR., Tormos, C *et al.* 2003. Antioxidant activities and oxidative stress byproducts in human hypertension. *Hypertension.* 41(5): pp. 1096–1101.

- Rembek, M., Goch, A., Goch, J. 2010. The clinical course of acute ST-elevation myocardial infarction in patients with hypertension. *Kardiologia Polska*. 68(2): pp. 157–163.
- Salgado, J.V., Souxa, F.L., Salgado, B.J. 2013. How to understand the association between cystatin C levels and cardiovascular disease: Imbalance, counterbalance, or consequence?. *Journal of Cardiology*. 62 (2013) 331–335.
- Seto, A.H., Shroff, A., Abu-Fadel, M., Blankeenship, J.C., Boudoulas, K.D., *et al.*, 2018. Length of stay following percutaneous coronary intervention: An expert consensus document update from the society for cardiovascular angiography and interventions. *Catheter. Cardiovasc. Interv.* 92: 717-31.
- Shankar, A., Teppala, S. 2011. Relationship Between Body Mass Index and High Cystatin Levels among US Adults. *J Clin Hypertens*. 13(12):925-30
- Shilpak, M.G., Mattes, M.D., Peralta, C.A. 2013. Update on Cystatin C: Incorporation Into Clinical Practice. *Am J Kidney Dis*. 62(3):595-603.
- Sigwart, U., Puel, J., Mirkovitch, V., Joffre, F., Kappenberger, L. 1987. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. *N. Engl. J. Med*. 316:701-6.
- Sjöström, P., Tidman, M., Jones, I. 2004. The shorter T_{1/2} of cystatin C explains the earlier change of its serum level compared to serum creatinine. *Clin. Nephrol*. 62, 241–2.
- Small, A., Klinke, P., Della-Siega, A., Fretz, E., Kinloch, D., *et al.*, 2007. Day procedure intervention is safe and complication free in higher risk patients undergoing transradial angioplasty and stenting. The DISCHARGE study. *Catheter. Cardiovasc. Interv.* 70: 907–12.
- Stone, G.W., McLaurin, B.T., Cox, D.A., Bertrand, M.E., Lincoff, A.M., Moses, J.W., *et al.*, 2006. Bivalirudin for patients with acute coronary syndromes. *N. Engl. J. Med*. 355:2203–16.
- Su, TH., Chang, SH., Chen, PC., Chan, YL. 2017. Temporal Trends in Treatment and Outcomes of Acute Myocardial Infarction in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Observational Study. *J Am Heart Assoc*. 6:e004525.
- Sudigdo, S. dan Ismael, S. 2016. Dasar-dasar metodologi penelitian klinis. Jakarta: *Sagung Seto.*
- Swaminathan, R.V., Rao, S.V., McCoy, L.A., Kim, L.K., Minutello, R.M. *et al.* 2015. Hospital Length of Stay and Clinical Outcomes in Older STEMI Patients After Primary PCI A (Report From the National Cardiovascular Data Registry). *Journal of The American College of Cardiology*. 65(12):1161-71.
- Tada, A., Omote, K., Nagai, T., Honda, Y., Nakano, H. *et al.* 2020. Prevalence, Determinants, and Prognostic Significance of Hospital Acquired Pneumonia in Patients with Acute Heart Failure. *Journal of Clinical Medicine*. 9:2219.
- Tanaga, K., Tarao, K., Nakamura, Y., Inoue, T., Jo, K. *et al.* 2012. Percutaneous coronary intervention causes increase of serum cystatin C concentration even in the patients with a low risk of contrast-induced nephropathy. *Cardiovasc Interv and Ther*. 27:168–173
- Teaford, H.R., Barreto, J.N., Vollmer, K.J., Rule, A.D., Barreto, E.N. 2020. Cystatin C: A Primer for Pharmacist. *Pharmacy*. 8: 35.
- Topol, E., Califf, R., Werf, F.V. *et al.* 1993. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *New England Journal of Medicine*. 329(10):pp. 673–682.

- Torry, SRV., Panda, AL., Ongkowijaya, J. 2013. Gambaran Faktor Resiko Penderita Sindrom Koroner Akut. Bagian/SMF Ilmu Penyakit Dalam Fakultas Kedokteran Unsrat. 1-8.
- Truffa, A.A.M., Granger, C.B., White, K.R., Newby, L.K., Mehta, R.H., Hochman, J.S., *et al.*, 2012. Serious Infection Following Acute Myocardial Infarction: Incidence, Clinical Features, and Outcomes. *JACC. Cardiovasc. Interv.* 5(7): doi:10.1016/j.jcin.2012.03.018.
- Tsai, T.T., Patel, U.D., Chang, T.I., Kennedy, K.F., Masoudi, F.A., *et al.*, 2014. Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: Insights from the national cardiovascular data registry Cath-PCI registry. *J. Am. Heart. Assoc.* 3: e001380.
- Vavalle, JP., Lopes, RD., Chen, AY., Newby, K., Wang, T., Shah, BR. 2012. Identifying Factors that Influence Hospital Length of Stay in Patients with Non-ST-segment Elevation Myocardial Infarction: Insights from the Acute Coronary Treatment Intervention Outcomes Network Registry®-Get With The Guidelines. *Am J Med.* 125(11): 2-3.
- Velagapudi, P., Kolte, D., Ather, K., Khera, S., Gupta, T., *et al.*, 2018. Temporal Trends and Factors Associated With Prolonged Length of Stay in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Am. J. Cardiol.* 122(2): 185-91.
- Wei, L., Ye, X., Pei, X., Wu, J., Zhao, W. 2014. Reference Intervals for Cystatin c serum and Factors Influencing Cystatin C Levels Other than Renal Function in the Elderly. *PLoS. ONE.* 9(1): 7-8.
- Wegiel, M., Dziewierz, A., Bakalaraz, JW., Sorysz, D., Surdacki, A., Bartus, S., *et al.*, 2018. Hospitalization Length after Myocardial Infarction: Risk-Assessment-Based Time of Hospital Discharge vs. Real Life Practice. 7(12): 9-10.
- Weisbord, S.D., Chen, H., Stone, R.A., Kip, K.E., Fine, M.J., *et al.*, 2006. Associations of Increases in Serum Creatinine with Mortality and Length of Hospital Stay after Coronary Angiography. *J. Am. Soc. Nephrol.* 17: 2871-7.
- Werner, N., Bauer, T., Hochadel, M., Zahn, R., Weidinger, F., Marco, J., *et al.*, 2013. Incidence and clinical impact of stroke complicating percutaneous coronary intervention results of the euro heart survey percutaneous coronary interventions registry. *Circ. Cardiovasc. Interv.* 6:362-9.
- Yadav, D., Sahu, AK., Khanna, R., Goel, PK. 2020. Impact of Percutaneous Coronary Intervention on Patients With Impaired Baseline Renal Function. *Indian Heart Journal.* 72:356-361.
- Yong, Z., Pei, X., Zhu, B., Yuan, H., Zhou, W. 2017. Predictive value of serum cystatin C for acute kidney injury in adults: a meta-analysis of prospective cohort trials. *Sci. Rep.:* 41012